Pfizer (NYSE:PFE) Stock Price Up 1% – What’s Next?

Pfizer Inc. (NYSE:PFE) was up 1% on Monday . The company traded as high as $27.19 and last traded at $27.04. Approximately 47,433,031 shares changed hands during trading, an increase of 12% from the average session volume of 42,529,801 shares. The stock had previously closed at $26.76.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s non-COVID portfolio grew 5% in the second quarter, and the company raised its 2026 outlook while targeting approximately $9.7 billion in savings. New launches, acquisitions and late-stage pipeline programs are intended to support growth from 2029 onward. Pfizer Q2 2026 Earnings Call Transcript
• Positive Sentiment: Positive Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo add potential value to Pfizer’s immunology pipeline and strengthen the company’s effort to reduce dependence on COVID-related products. Pfizer Agreed to a $44 Million Chantix Settlement
• Positive Sentiment: Erste Group raised its 2026 EPS estimate for Pfizer to $2.95 from $2.92, broadly in line with the $2.97 consensus estimate, signaling modestly improved analyst expectations. Pfizer Analyst Estimate Update
• Neutral Sentiment: Pfizer’s acquisitions and broader pipeline are reshaping its post-COVID strategy. Investors are encouraged by the potential growth platform, but much of the payoff is expected several years in the future. Pfizer Acquisitions Reshape Its Healthcare Strategy
• Negative Sentiment: The 2026 guidance increase reportedly relies heavily on a product approaching patent expiry, raising concerns about the durability of earnings and the timing of replacement revenue. Pfizer Raised Its 2026 Guidance
• Negative Sentiment: Pfizer agreed to a $44 million Chantix class-action settlement, while Arbutus reported new international patent-enforcement lawsuits against Pfizer and BioNTech involving lipid nanoparticle technology. These matters add to legal and product-related uncertainty, although the Chantix payment is modest relative to Pfizer’s size. Arbutus Corporate Update

Wall Street Analyst Weigh In

Several analysts recently commented on PFE shares. Guggenheim dropped their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. BMO Capital Markets cut their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Trading Down 1.2%

The stock has a market cap of $149.90 billion, a PE ratio of 34.61 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a 50 day moving average of $25.07 and a two-hundred day moving average of $26.18.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the business posted $0.78 earnings per share. Pfizer’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the 4th quarter worth about $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the 2nd quarter worth about $26,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC raised its holdings in shares of Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 650 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.